StemCells has reached a critical juncture in its development program with a highly encouraging interim analysis of its Phase II PATHWAY study pointing to promising efficacy in cohort 1 of its human central nervous system stem cells (HuCNS-SC) in lead indication spinal cord injury (SCI). Given limited financial resources, StemCells is realigning operations to focus efforts on the internal funding for key pivotal Phase III SCI trials. New group leadership by way of a recently announced change i
05 Feb 2016
Critical juncture in spinal cord injury
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Critical juncture in spinal cord injury
SThree plc (STEM:LON) | 426 -19.2 (-1.0%) | Mkt Cap: 575.2m
- Published:
05 Feb 2016 -
Author:
Neil Basten -
Pages:
6
StemCells has reached a critical juncture in its development program with a highly encouraging interim analysis of its Phase II PATHWAY study pointing to promising efficacy in cohort 1 of its human central nervous system stem cells (HuCNS-SC) in lead indication spinal cord injury (SCI). Given limited financial resources, StemCells is realigning operations to focus efforts on the internal funding for key pivotal Phase III SCI trials. New group leadership by way of a recently announced change i